

Vertex Pharmaceuticals Inc. MA (VRTX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000875320

Vertex Pharmaceuticals Inc. MA VRTX; healthcare	
Grade	A A B C D E strongest fifth of 371 graded peers percentile 15.4; sampling error 2.5 points; lower is stronger
Rank	58 of 371
Profitability	B/C percentile 41.9
Solvency	B percentile 25.1
Growth and financing	C percentile 43.0
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$25.6B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: fortress balance sheet
Inputs computable	11 of 14
Graded from	filings received through Feb 13, 2026 238 days before the rescans; latest periodic filing 10-Q received Aug 4, 2026
Last close	\$503.17 2026-10-08; market equity \$127.5B
Price used in grade	None



A, the bull
 strongest fifth of its sector;
 letters are fifths of the 371
 graded peers

Share price, twelve months to the rescans


split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: A from Feb 21, 2020, A/B from Feb 21, 2026, B from Mar 21,

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 13, 2026

We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. We have approved medicines for cystic fibrosis ("CF"), sickle cell disease ("SCD"), transfusion dependent beta thalassemia ("TDT"), and acute pain, and we continue to serially innovate and advance next-generation clinical and research programs in these areas.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 41.9						
Gross profitability		40.4%	32.2%	32.3	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		1.3%	(6.6%)	83.0	811	2025-12-31
Gross margin stability, five years		0.8 pts	2.8 pts	10.3	243	2025-12-31
Solvency, sleeve percentile 25.1						
Twelve-month failure probability		0.02%	0.07%	5.7	248	2026-06-30
Altman Z double-prime		7.50	(0.31)	12.7	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2020-12-31; latest annual assets end 2025-12-31
Current ratio		2.90x	2.96x	56.8	839	2025-12-31
Growth and financing, sleeve percentile 43.0						
Revenue growth, three-year compound		10.4%	10.0%	49.5	415	2025-12-31
Free cash flow growth, three-year compound		(6.6%)	10.9%	81.1	96	2025-12-31
Reinvestment rate		43.2%	37.1%	46.6	104	2025-12-31
Asset growth, three years		12.2%	2.1%	28.6	704	2025-12-31
Net share issuance, one year		(1.1%)	2.5%	9.0	634	2026-02-06

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
53	Janux Therapeutics, Inc. (JANX)	14.1	A	
54	Treace Medical Concepts, Inc. (TMCI)	14.3	A	
55	Lantheus Holdings, Inc. (LNTH)	14.6	A	
56	Harrow, Inc. (HROW)	14.9	A	late filer
57	Edwards Lifesciences Corp. (EW)	15.1	A	
58	Vertex Pharmaceuticals Inc. MA (VRTX) <	15.4	A	
59	CareDx, Inc. (CDNA)	15.7	A	
60	Ensign Group, Inc. (ENSG)	15.9	A	fortress balance sheet

61	RxSight, Inc. (RXST)	16.2	A	fortress
				balance sheet
62	Definium Therapeutics, Inc. (DFTX)	16.5	A	dilution
63	Natures Sunshine Products Inc. (NATR)	16.8	A	fortress
				balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	39.0%	8.0%	70
Distance from 52-week high	(9.8%)	(31.4%)	84
EBIT to enterprise value	3.4%	(1.5%)	69
Free cash flow yield	2.5%	(1.0%)	67
Book value to price	0.16	0.28	35
Sales to price	0.09	0.31	24
Composite equity issuance, five years	(2.5%)	20.3%	24
Relative strength against the sector, log excess return	0.12	(0.14)	70

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$6.1B
Operating cash flow, four quarters	\$4.3B
Months of runway	not finite
Days since last periodic filing	66 (10-Q received Aug 4, 2026)
Median daily dollar volume, 63 sessions	\$534.2M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$12.0B	2025-12-31	2026-02-13	10-K	0000875320-26-000056
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$1.7B	2025-12-31	2026-02-13	10-K	0000875320-26-000056
3	assets	us-gaap:Assets	\$25.6B	2025-12-31	2026-02-13	10-K	0000875320-26-000056
4	net income	us-gaap:NetIncomeLoss	\$4.0B	2025-12-31	2026-02-13	10-K	0000875320-26-000056
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$3.6B	2025-12-31	2026-02-13	10-K	0000875320-26-000056
6	assets	us-gaap:Assets	\$22.5B	2024-12-31	2026-02-13	10-K	0000875320-26-000056
7	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$11.0B	2024-12-31	2026-02-13	10-K	0000875320-26-000056
8	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$1.5B	2024-12-31	2026-02-13	10-K	0000875320-26-000056
9	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$9.9B	2023-12-31	2026-02-13	10-K	0000875320-26-000056
10	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$1.3B	2023-12-31	2026-02-13	10-K	0000875320-26-000056
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$8.9B	2022-12-31	2025-02-13	10-K	0000875320-25-000053
12	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$1.1B	2022-12-31	2025-02-13	10-K	0000875320-25-000053
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$7.6B	2021-12-31	2024-02-15	10-K	0000875320-24-000062
14	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$904.2M	2021-12-31	2024-02-15	10-K	0000875320-24-000062
15	current assets	us-gaap:AssetsCurrent	\$11.2B	2025-12-31	2026-02-13	10-K	0000875320-26-000056
16	current liabilities	us-gaap:LiabilitiesCurrent	\$3.9B	2025-12-31	2026-02-13	10-K	0000875320-26-000056
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$13.6B	2025-12-31	2026-02-13	10-K	0000875320-26-000056

18	operating income	us-gaap:OperatingIncomeLoss	\$4.2B	2025-12-31	2026-02-13	10-K	0000875320-26-000056
19	book equity	us-gaap:StockholdersEquity	\$18.7B	2025-12-31	2026-02-13	10-K	0000875320-26-000056
20	liabilities	us-gaap:Liabilities	\$7.0B	2025-12-31	2026-02-13	10-K	0000875320-26-000056
21	operating income	us-gaap:OperatingIncomeLoss	\$2.9B	2020-12-31	2023-02-10	10-K	0000875320-23-000007
22	interest expense	us-gaap:InterestExpense	\$58.2M	2020-12-31	2021-02-11	10-K	0000875320-21-000006
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$437.6M	2025-12-31	2026-02-13	10-K	0000875320-26-000056
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$492.6M	2024-12-31	2026-02-13	10-K	0000875320-26-000056
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$297.7M	2024-12-31	2026-02-13	10-K	0000875320-26-000056
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$3.5B	2023-12-31	2026-02-13	10-K	0000875320-26-000056
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$200.4M	2023-12-31	2026-02-13	10-K	0000875320-26-000056
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$4.1B	2022-12-31	2025-02-13	10-K	0000875320-25-000053
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$204.7M	2022-12-31	2025-02-13	10-K	0000875320-25-000053
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$209.8M	2025-12-31	2026-02-13	10-K	0000875320-26-000056
31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$4.6B	2025-12-31	2026-02-13	10-K	0000875320-26-000056
32	income tax	us-gaap:IncomeTaxExpenseBenefit	\$690.0M	2025-12-31	2026-02-13	10-K	0000875320-26-000056
33	current assets	us-gaap:AssetsCurrent	\$9.6B	2024-12-31	2026-02-13	10-K	0000875320-26-000056
34	current liabilities	us-gaap:LiabilitiesCurrent	\$3.6B	2024-12-31	2026-02-13	10-K	0000875320-26-000056
35	assets	us-gaap:Assets	\$22.7B	2023-12-31	2025-02-13	10-K	0000875320-25-000053
36	assets	us-gaap:Assets	\$18.2B	2022-12-31	2024-02-15	10-K	0000875320-24-000062
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	254,034,190	2026-02-06	2026-02-13	10-K	0000875320-26-000056
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	256,789,869	2025-02-07	2025-02-13	10-K	0000875320-25-000053